About this trial
Background:
Immunotherapy is a type of treatment that works by making the body s own immune system stronger. These treatments are used for cancers such as non small cell lung cancer (NSCLC); thymic carcinoma (TC); or metastatic castrate-resistant prostate cancer (mCRPC). But these cancers may still come back after treatment.
Objective:
To test a new immunotherapy drug (STAR0602), alone or combined with an approved drug (nivolumab), in people with NSCLC, mCRPC, or TC.
Eligibility:
People aged 18 years or older with NSCLC, mCRPC, or TC that did not respond to treatment or returned after treatment.
Design: Participants will be screened. They will have blood and urine tests. They will have imaging scans and a test of their heart function.
STAR0602 and nivolumab are given through a needle inserted into a vein (infusion). Participants will be treated in 28-day cycles. They will receive infusions of 1 or both drugs on the first and 15th day of each cycle. They will remain in the hospital for up to 5 days after their first 2 infusions of STAR0602.
Imaging scans, blood tests, and other tests may be repeated during study visits. Participants may opt to have tissue samples (biopsies) taken from their tumors. Some blood and tissue samples may be used for genetic tests.
Participants may continue getting STAR0602 for up to 2 years and nivolumab for up to 6 months.
Participants will have an end-of-study visit within 1 month, and follow-up phone calls 1 month and 3 months, after they stop the study drug. Long-term follow-up calls and visits will continue every 3 to 6 months for up to 5 years.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants must have histologically or cytologically confirmed NSCLC, mCRPC, or TC (by outside pathology report or via the NCI Laboratory of Pathology [LP]) that is unresectable, locally-advanced, or metastatic, and for which standard curative therapies do not exist or are no longer effective. Progressive disease must be documented prior to study entry.
NSCLC: Participants must have received at least one prior approved line of standard therapy. Receipt of prior immune checkpoint inhibitors (ICI) is required unless the participant has a known targetable oncogenic abnormality (e.g., targetable EGFR mutations, KRAS G12C, ALK rearrangement, ROS1 rearrangement, BRAF V600E mutation, NTRK 1/2/3 gene fusion, METex14 skipping mutation, RET rearrangement, ERBB2 [HER2], NRG1 gene fusion) that has been treated with appropriate targeted therapy. Prior ICI therapy is not required for participants with NSCLC harboring a targetable oncogenic abnormality.
mCRPC: Participants must have received at least one prior line of treatment with enzalutamide and/or abiraterone with the exception of participants who were treated with docetaxel and androgen deprivation therapy (ADT) for mCRPC and progressed on docetaxel treatment or who progressed within one month of the last docetaxel dose. Participants must agree to continue ADT with a gonadotropin-releasing hormone analogue/antagonist or bilateral orchiectomy.
TC: Participants should have received at least one prior line of standard therapy such as platinum-based chemotherapy. For participants who refuse cytotoxic chemotherapy, a rationale for refusal to receive standard first-line therapy will be captured in the case report form and the medical record. Receipt of prior ICI is permitted.
Disqualifiers
History of allergic reactions attributed to compounds of similar chemical or biologic composition to STAR0602, or other agents used in study.
Detectable acetylcholine receptor autoantibodies or anti-striational antibodies due to the risk of immune myositis (for participants with TC only).
Persisting toxicity related to prior therapy (NCI CTCAE Grade > 1 or baseline) with the exception of, alopecia, sensory neuropathy Grade <= 2 and hearing loss Grade <= 2. Note: Prior ICI-related endocrine abnormalities are permitted regardless of grade if receiving replacement therapy.
Participants with history of prior ICI-related Grade > 3 pneumonitis, pericarditis, myocarditis, colitis or any neurological or neuromuscular toxicities.
Trial design
Parallel
Treatments tested in this trial
STAR0602
DrugSTAR0602 is given intravenously (IV) on day 1 and 15 of every 28-day cycle for up to 24 months (24 cycles)
Nivolumab
DrugNivolumab is given intravenously (IV) on day 1 and 15 of every 28-day cycle (with the exception of cycle 1 where nivolumab will only be administered on day 15) for up to 6 months (6 cycles)
Treatment groups
Trial outcomes
Primary outcomes
Phase Ib: Determine the safety of STAR0602 monotherapy in participants with TC, and safety of STAR0602 in combination with nivolumab in participants with NSCLC with or without targetable genomic alterations or mCRPC
The number of adverse events by grade and type will be reported in each cohort along with a 95% confidence interval. Dose-limiting toxicities (DLTs) will also be collected and reported by type, grade, and frequency.
Phase II: Determine the clinical efficacy of STAR0602 alone in participants with TC measured by progression free survival (PFS)
Proportion of participants attaining progression free survival (PFS) will be evaluated and reported along with a 95% confidence interval.
Secondary outcomes
To evaluate safety of STAR0602 alone during Phase II
The number of adverse events by grade and type will be reported in each cohort along with a 95% confidence interval. Dose-limiting toxicities (DLTs) will also be collected and reported by type, grade, and frequency.
To evaluate the efficacy of STAR0602 + nivolumab as defined by progression free survival (PFS) in participants with NSCLC or mCRPC
Proportion of participants attaining progression free survival (PFS) will be evaluated and reported along with a 95% confidence interval.
Determine the overall response rate (ORR), disease control rate (DCR), duration of response (DOR), and overall survival (OS) of STAR0602 + nivolumab in participants with NSCLC or mCRPC
Overall response rate (ORR), disease control rate (DCR), duration of response (DOR), and overall survival (OS) will be calculated as simple proportions from the on-study date and reported along with a 95% confidence interval for the median time if appropriate, or for selected time points such as at 1 or 2 years.
Determine the overall response rate (ORR), disease control rate (DCR), duration of response (DOR), and overall survival (OS) of STAR0602 in participants with TC
Overall response rate (ORR), disease control rate (DCR), duration of response (DOR), and overall survival (OS) will be calculated as simple proportions from the on-study date and reported along with a 95% confidence interval for the median time if appropriate, or for selected time points such as at 1 or 2 years.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: